title: P2Y12 receptor antagonists in acute coronary syndrome: clinical implications of pharmacologic and pharmacogenetic differences.
abstract: Platelet activation and aggregation are key events in the pathophysiological process of thrombosis, and vascular occlusions. Antiplatelet therapy has proven to be crucial for managing patients with acute coronary syndromes, coronary artery disease and in patients undergoing percutaneous coronary interventions. However, residual platelet reactivity on antiplatelet treatment confers a five-fold increased risk of major adverse cardiovascular events which indicates a need for more effective antiplatelet medications to address the substantial burden of cardiovascular disease. This article reviews the P2Y(12) receptor antagonists with regards to pharmacologic and pharmacogenetic differences and their clinical implications along with the discussion of recent patents.
authors.affiliation: Department of Cardiology, Chicago Medical School, North Chicago, Illinois, USA. drmukeshsingh@yahoo.com
authors.forename: Mukesh
authors.initials: M
authors.lastname: Singh
authors.forename: Sasikanth
authors.initials: S
authors.lastname: Adigopula
authors.forename: Niaz
authors.initials: N
authors.lastname: Ahmad
authors.forename: Rohit
authors.initials: R
authors.lastname: Arora
authors.forename: Sandeep
authors.initials: S
authors.lastname: Khosla
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D015906:Angioplasty, Balloon, Coronary / Q000379:methods; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism; D003324:Coronary Artery Disease / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D010330:Patents as Topic; D010597:Pharmacogenetics; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000494:pharmacology; D058921:Purinergic P2Y Receptor Antagonists / Q000009:adverse effects / Q000494:pharmacology*; D058925:Receptors, Purinergic P2Y12 / Q000187:drug effects* / Q000378:metabolism
chemical_list: D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists; D058925:Receptors, Purinergic P2Y12